Primaquine

Generic Name
Primaquine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C15H21N3O
CAS Number
90-34-6
Unique Ingredient Identifier
MVR3634GX1
Background

An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI dis...

Indication

For the treatment of malaria.

Associated Conditions
Malaria, Malaria caused by Plasmodium ovale, Malaria caused by plasmodium vivax, Pneumocystis Jirovecii Pneumonia
Associated Therapies
-
Clinical Trials
Related News

Controlled Human Malaria Infection Transmission Model - Phase A

First Posted Date
2020-02-21
Last Posted Date
2024-05-23
Lead Sponsor
University of Oxford
Target Recruit Count
44
Registration Number
NCT04280692
Locations
🇰🇪

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Biomarkers of P. Vivax Relapse

Not Applicable
Recruiting
Conditions
Vivax Malaria
Relapse
Malaria
CYP2D6 Polymorphism
Interventions
Drug: Primaquine
First Posted Date
2020-01-14
Last Posted Date
2020-01-14
Lead Sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Target Recruit Count
100
Registration Number
NCT04228315
Locations
🇹🇭

Khun Han Hospital, Khun Han, Thailand

TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

First Posted Date
2020-01-09
Last Posted Date
2023-07-21
Lead Sponsor
Research Institute for Tropical Medicine, Philippines
Target Recruit Count
159
Registration Number
NCT04222088

Short Course Radical Cure of P. Vivax Malaria in Nepal

Phase 4
Completed
Conditions
Malaria
Malaria, Vivax
Malaria,Falciparum
Interventions
Drug: primaquine
First Posted Date
2019-09-06
Last Posted Date
2024-08-29
Lead Sponsor
Menzies School of Health Research
Target Recruit Count
27
Registration Number
NCT04079621
Locations
🇳🇵

Tikapur Hospital, Tikapur, Nepal

🇳🇵

Malakheti Hospital, Malakheti, Nepal

Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas

Phase 4
Completed
Conditions
Falciparum Malaria
Malaria
Vivax Malaria
Interventions
Drug: primaquine
First Posted Date
2019-04-16
Last Posted Date
2023-11-21
Lead Sponsor
Menzies School of Health Research
Target Recruit Count
500
Registration Number
NCT03916003
Locations
🇪🇹

Arba Minch University, Arba Minch, Ethiopia

🇧🇩

Icddrb, Upazila, Bangladesh

🇮🇩

Puskesmas Mangili, Dusun Tenggara, Indonesia

Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil

Not Applicable
Completed
Conditions
Malaria, Vivax
P Vivax
Interventions
Drug: Primaquine
First Posted Date
2018-08-01
Last Posted Date
2021-08-09
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
257
Registration Number
NCT03610399
Locations
🇧🇷

Hospital do Jurua, Cruzeiro do Sul, Brazil

Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients

Phase 2
Active, not recruiting
Conditions
Vivax Malaria
G6PD Deficiency
Interventions
Drug: Chloroquine
Drug: Primaquine
First Posted Date
2018-05-18
Last Posted Date
2023-03-29
Lead Sponsor
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Target Recruit Count
106
Registration Number
NCT03529396
Locations
🇧🇷

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil

🇧🇷

Centro de Pesquisa em Medicina Tropical (Cepem), Porto Velho, RO, Brazil

Single Low-dose Primaquine Efficacy and Safety.

Phase 4
Completed
Conditions
Malaria
Interventions
Drug: Primaquine
First Posted Date
2017-11-24
Last Posted Date
2023-02-24
Lead Sponsor
Tropical Pesticides Research Institute, Tanzania
Target Recruit Count
157
Registration Number
NCT03352843
Locations
🇹🇿

Tropical Pesticides Research Institute (TPRI), Arusha, Tanzania

Assessing a Risk Model for G6PD Deficiency

First Posted Date
2017-11-08
Last Posted Date
2021-11-12
Lead Sponsor
PATH
Target Recruit Count
54
Registration Number
NCT03337152
Locations
🇹🇭

Shoklo Malaria Research Unit (SMRU), Mae Sot, Thailand

Genetic Variability in CYP2D6 in U.S Active Duty Population

Phase 1
Completed
Conditions
Pharmacologic Action
Interventions
Drug: Primaquine
First Posted Date
2016-11-09
Last Posted Date
2021-10-20
Lead Sponsor
Walter Reed Army Institute of Research (WRAIR)
Target Recruit Count
550
Registration Number
NCT02960568
Locations
🇺🇸

WRAIR, Silver Spring, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy